Eupraxia Says Regulators In Australia And Canada Have Cleared Request To Expand Its Phase 1b/2a Resolve Trial
Portfolio Pulse from Benzinga Newsdesk
Eupraxia Pharmaceuticals announced that regulators in Australia and Canada have approved the expansion of its Phase 1b/2a Resolve trial.
May 23, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eupraxia Pharmaceuticals has received regulatory approval from Australia and Canada to expand its Phase 1b/2a Resolve trial, which could accelerate the development of its clinical programs.
The regulatory approval to expand the trial is a significant milestone for Eupraxia Pharmaceuticals, potentially accelerating the development of its clinical programs and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100